Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07251465 · ClinicalTrials.gov registry record
A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
A clinical trial, sponsored by Pfizer.
- Active
- Registry status
- 846,279
- Enrollment target
NCT07251465 is a clinical trial that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 846,279 participants.
The verdict
NCT07251465 is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 846,279 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how effective is PCV20 to help stop adults from getting pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be actively enrolled. The information of participants will be taken from Kaiser Permanente Southern California's (KPSC) electronic health records (EHR). We will look at the EHR information for adults who meet the following points: * 18 years of age or older and a KPSC member as of 01 July 2022. * have been a KPSC member for at least one year before 01 July 2022. * have not received PCV15. * have had pneumonia or lower respiratory tract infection within 30 days of 01 July 2022. The study will begin from 01 July 2022 and will be followed through 30 June 2025. At the end of the follow-up period, the study will compare the number of pneumonia cases among people who receive PCV20 who do not receive it.
Interventions
- BIOLOGICAL Receipt of PCV20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 846,279 participants |
| Start Date | 2026-01-21 |
| Est. Completion | 2026-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07251465
The ClinicalTrials.gov registry entry for NCT07251465 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 846,279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Receipt of PCV20 is the first listed.
NCT07251465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07251465 about?
NCT07251465 is a clinical study titled "A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia". The purpose of this study is to learn how effective is PCV20 to help stop adults from getting pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be actively enrolled. The ...
What is the current status of trial NCT07251465?
This trial is currently active not recruiting. The enrollment target is 846,279 participants. The study started on 2026-01-21. Estimated completion is 2026-07-31.
What interventions are being tested in trial NCT07251465?
The interventions under investigation include: Receipt of PCV20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07251465?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.